MYO vs OSUR vs HOLX vs BFLY

For growth investors, Myomo, Inc.

(MYO) is the stronger pick with 25. 7% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Butterfly Network, Inc. (BFLY) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -90. 9% for Myomo, Inc. (MYO). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus MYO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Butterfly Network, Inc. 's 3. 28β — meaning BFLY is approximately 697% more volatile than HOLX relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 170% for Myomo, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Myomo, Inc.

(MYO) is pulling ahead at 25. 7% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: Butterfly Network, Inc. grew EPS 8. 8% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, MYO leads at 38. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -79. 0% for Butterfly Network, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -88. 5% for BFLY. At the gross margin level — before operating expenses — MYO leads at 65. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BFLY: 27.

8% to $5. 42.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Butterfly Network, Inc. (BFLY) carries a higher beta of 3. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, BFLY: -57. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MYO is a small-cap high-growth stock; OSUR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; BFLY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.